Home monitoring of implantable cardioverter-defibrillators: interpretation reliability of the second-generation “IEGM Online” system

Herbert Nägele1*, Jolana Lipoldová2, Hanno Oswald3, Gunnar Klein3†, Arif Elvan4, Ernst Vester5, Wolfgang Bauer6, Hansjürgen Bondke7, Sebastian Reif8, Claudia Daub9, Frank Menzel10, Jürgen Schrader11, and Göran Zach12

1Medical Clinic, Hospital Reinbek St. Adolf Stift, Reinbek, Germany; 2St. Anne’s University Hospital and International Clinical Research Center, Brno, Czech Republic; 3Hannover Medical School, Hannover, Germany; 4Department of Cardiology, Isala Kliniken, Zwolle, The Netherlands; 5Evangelisches Krankenhaus, Düsseldorf, Germany; 6Department of Internal Medicine I and Comprehensive Heart Failure Centre, University Hospital Würzburg, Würzburg, Germany; 7Charité - University Medicine Berlin, Campus Charité Mitte, Berlin, Germany; 8Department of Cardiology, Städtisches Klinikum München-Bogenhausen, Munich, Germany; 9Elisabeth-Krankenhaus, Recklinghausen, Germany; 10Klinikum Frankfurt (Oder), Frankfurt (Oder), Germany; 11Biotronik SE and Co. KG, Berlin, Germany; and 12Department of Internal Medicine, LKH Bruck an der Mur, Bruck an der Mur, Austria

Received 30 June 2014; accepted after revision 10 November 2014; online publish-ahead-of-print 7 January 2015

Aims
Intracardiac electrograms (IEGMs) are essential for the assessment of implantable cardioverter-defibrillator (ICD) function. The Biotronik Home Monitoring systems transmit an ‘IEGM Online’ that is shorter than the full-length programmer IEGM due to technical constrains. The aim of this study was to evaluate the accuracy of the physician’s classification of the underlying rhythm based on the second-generation IEGM Online.

Methods and results
In total, 1533 patients treated with single- and dual-chamber ICDs and cardiac resynchronization therapy defibrillators were enrolled at 67 investigational sites and followed for 15 months. The investigators classified the rhythm shown in IEGM Online as ventricular tachycardia, ventricular fibrillation, atrial fibrillation, other supraventricular tachyarrhythmia, oversensing due to lead failure, T-wave oversensing, or other rhythm. At the next in-office follow-up, the investigators classified independently the rhythm seen in the corresponding programmer IEGM. The two rhythm classifications were compared thereafter. Both IEGM Online and programmer IEGM were available in 2099 arrhythmic or oversensing events, of which 146 (7.0%) were classified as other rhythm or artefacts and were excluded as inconclusive or atypical. The remaining 1953 events, affecting 352 patients (23.0%), were classified correctly in 1803 cases (92.3%). The accuracy of rough rhythm classification as ventricular, supraventricular, or oversensing was 97.2%.

Conclusion
The Lumax and IEGM Online HD Evaluation study demonstrates that remote IEGM analysis is reasonably accurate in a remote monitoring system that transmits shorter IEGM than the full-length programmer IEGM for the sake of frequent, fully automatic data transmission.

Keywords
Implantable cardioverter-defibrillator • Intracardiac electrogram • Arrhythmia detection • Telemedicine • Remote monitoring • Home monitoring

* Corresponding author. Albertinen Herz- und Gefäßzentrum, Süntelstr. 11a, D – 22457 Hamburg. Tel: +49 40 5588 6427; fax: +49 40 5588 2322. E-mail address: herbert.naegle@albertinen.de
† The present address of G.K. is Heart Center Hannover, Schmiedestraße 18, 30159 Hannover, Germany.
© The Author 2015. Published by Oxford University Press on behalf of the European Society of Cardiology.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
Introduction
Intracardiac electrograms (IEGMs) recorded upon arrhythmia detection by implantable cardioverter-defibrillators (ICDs) are essential for the assessment of the patient’s status and the appropriateness of arrhythmia classification and device therapy, and are thus indispensable for the management of patients with an ICD. The implementation of remote management in these patients requires the transmission of IEGMs by remote monitoring systems.

Automatic, daily Biotronik Home Monitoring technology includes IEGM as part of the transmitted ICD diagnostic data. The first-generation ‘IEGM Online’, which covered 3–10 s of compressed right ventricular electrogram before arrhythmia detection, was evaluated in the ‘Reliability of IEGM Online Interpretation’ (RIONI) study. After exclusion of 12.4% of events as inconclusive, the rest was classified correctly in 93.4% and incorrectly in 6.6%.

To improve remote IEGM interpretation, the second-generation ‘IEGM Online HD’ was introduced. It is multi-channel and uncompressed, has the same sample rate and layout as the programmer IEGM, and covers 10–20 s before arrhythmia detection and additional 5–10 s after episode termination. The reliability of the second-generation IEGM Online has not been investigated. Thus, this study was undertaken to evaluate in a real-world setting the interpretation reliability of a large sample of transmitted IEGMs.

Methods
The ‘Lumax and IEGM Online HD Evaluation’ (LION) study was a prospective, international, non-randomized investigation aimed at assessing the percentage of correct classification of IEGM Online HD in a real-world setting. Lumax and IEGM Online HD Evaluation was conducted in compliance with Good Clinical Practice guidelines and the Declaration of Helsinki. The study protocol was approved by appropriate national and local ethics committees. Patients gave their written informed consent before enrollment.

Patient selection
Patients with an accepted indication for the implantation of an ICD or cardiac resynchronization therapy defibrillator (CRT-D) were eligible for enrollment up to three months after device implantation. Additional study inclusion criteria were the patient’s stable medical status, geographical stability, and ability and willingness to attend all follow-ups. Exclusion criteria were a life expectancy shorter than 6 months, inability to handle the Home Monitoring system, living in an area lacking the GSM mobile phone coverage, age < 18 years, or participation in another clinical study.

Devices
Patients received an ICD or a CRT-D from the Lumax family (Biotronik SE & Co. KG), capable of transmitting device diagnostic data at a programmed time every day (e.g. 3 a.m.) and upon detection of a relevant arrhythmic or technical event. A mobile phone-like patient device receives these data and relays them automatically over GSM mobile phone links to the Biotronik Home Monitoring Service Center. At this centre, data incoming from all countries are processed automatically and posted on a secure internet site accessible to patients’ physicians. Additional event notifications are sent to patients’ physicians per email or SMS for pre-specified events such as supraventricular or ventricular tachyarrhythmia.

An IEGM Online HD (HD = ‘high definition’) is automatically transmitted to the Service Center after device detection of an episode classified as ventricular or supraventricular tachyarrhythmia (SVT). It consists of marker channels, episode details, and uncompressed electrogram recordings from the left ventricular lead (CRT-D), right atrial lead (dual-chamber ICD and CRT-D), and right ventricular lead (all device types) (Figure 1). Because this remote monitoring system was designed for frequent transmissions, data quantities are carefully controlled to limit the energy consumption of the implanted devices. To this end, the original IEGM length of up to 180 s, stored in the device memory, is shortened in the IEGM Online HD to 10–20 s before arrhythmia detection and 5–10 s after episode termination.

Follow-up
Patient management was left to the attending physician’s discretion. All in-office follow-ups, whether regular or additional, had to be documented.

To reflect real-world situation, there was no core lab, but IEGMs were interpreted by clinical investigators. They were asked to classify the rhythm seen in IEGM Online HD within two working days of the corresponding event notification. During in-office follow-up, they independently classified the rhythm seen in the programmer IEGM of all available episodes. The classification of rhythms in ICD IEGMs is mostly based on cycle length and regularity because less morphology information is available than in ECG. The device’s own rhythm classification was not used for IEGM classification.

Six episode categories were pre-defined for classification: ventricular tachycardia (VT), ventricular fibrillation (VF), atrial fibrillation (AF), other SVT, oversensing due to lead failure, and T-wave oversensing. Episodes matching none of these were reported as ‘other rhythm or artefacts’.

Study objective
Study objective was to investigate if the rhythm classification based on IEGM Online HD was equivalent to the rhythm classification based on the programmer IEGM.

Reliability of IEGM Online Interpretation study
The IEGM Online HD, which was investigated in this study, is the direct successor of the first-generation IEGM Online, which was investigated in the RIONI study. In that study, an expert board classified a sample of 210 IEGM Online strips into the three episode categories ventricular, supraventricular, or oversensing events. After exclusion of 12.4% of events as inconclusive, the rest was classified correctly in 93.4% and incorrectly in 6.6% (verified against the full-length programmer IEGMs). The results from our study will be compared with the RIONI results.
Figure 1 ‘IEGM Online HD’ obtained from a cardiac resynchronization therapy defibrillator device (Lumax HF-T, Biotronik). Upper panel, before episode detection. Lower panel, after episode termination. Both panels are shortened here to obtain acceptable figure size with readable letters and numbers. The numbers in the marker channels indicate P-P and R-R intervals in ms. Right ventricular arrhythmia markers VT1, VT2, and VF indicate fulfilling of the detection zone according to the implant’s programming. A, atrium; Ars, atrial refractory sensed beat; As, atrial sensed beat; ATP, anti-tachycardia pacing; LV, left ventricle; LVp, left ventricular paced beat; LVs, left ventricular sensed beat; RV, right ventricle; RVs, right ventricular sensed beat; RVp, right ventricular paced beat; VF, ventricular fibrillation; VT1, slow ventricular tachycardia; VT2, fast ventricular tachycardia.
Table 1  Baseline patient characteristics (n = 1537)

| Characteristic                        | N (%) | ± SD   |
|--------------------------------------|-------|-------|
| Age (years)                          | 64 ± 12 |       |
| Male                                 | 1263 (82) |     |
| Ejection fraction (%)                | 32 ± 12 |       |
| NYHA functional class                |       |       |
| I                                    | 141 (9)  |       |
| II                                   | 507 (33) |       |
| III                                  | 481 (31) |       |
| IV                                   | 18 (1)   |       |
| No heart failure                     | 99 (6)   |       |
| Not evaluated                        | 287 (19) |       |
| Underlying disease                   |       |       |
| Ischaemic heart disease              | 900 (59) |       |
| Cardiomyopathy                       | 1006 (66) |     |
| Diabetes                             | 452 (30)  |       |
| Renal insufficiency                  | 353 (23)  |       |
| History of AFIB                      | 422 (28)  |       |
| Medication                           |       |       |
| Beta-blocker                         | 1344 (88) |       |
| ACE-inhibitor or angiotensin-antagonist| 1270 (83) |     |
| Diuretic                             | 1174 (77) |     |
| Class I or III antiarrhythmic drug   | 335 (22)  |       |
| Ca-antagonist                        | 133 (9)   |       |
| Digital                              | 305 (20)  |       |
| Anticoagulant                        | 667 (44)  |       |
| Platelet aggregation inhibitor       | 816 (53)  |       |
| Secondary prevention ICD indication  | 598 (39)  |       |
| Implanted device                     |       |       |
| Single-chamber ICD                   | 717 (47)  |       |
| Dual-chamber ICD                     | 361 (24)  |       |
| CRT-D                                | 452 (30)  |       |

ACE, angiotensin-converting enzyme; AFIB, atrial fibrillation; CRT-D, cardiac resynchronization therapy defibrillator; ICD, implantable cardioverter-defibrillator; NYHA, New York Heart Association; SD, standard deviation.  
*aReported in 1236 patients.  
*bReported in 1530 patients.

Statistical methods

No study hypothesis was specified. A sample size of 1500 patients followed for 15 months was deemed sufficient for the given study objective. Episodes reported as other rhythm or artefacts based on any IEGM were excluded from the analysis as inconclusive or atypical. Data are shown as absolute values, percentages, means with standard deviation, and median with interquartile range. The χ² test was used to compare LION and RIONI study results. P value of < 0.05 was considered statistically significant. The analyses were conducted with the IBM SPSS 21 for Windows (IBM Corporation, Armonk) statistical software.

Results

Between March 2007 and February 2012, a total of 1533 patients were enrolled in the LION study at 67 investigational sites in seven European countries (see Supplementary material online, Appendix).

Forty-seven percent of patients had a single-chamber ICD, 24% a dual-chamber ICD, and 30% a CRT-D. At baseline, the patients presented with characteristics and medical history of a typical ICD population (Table 1). The proportion of patients with a secondary prevention indication was 39%. Two-thirds of patients had New York Heart Association (NYHA) class II–IV heart failure.

The cumulative follow-up was 1749 years. The median follow-up period was 455 days (interquartile range, 420–482). Both IEGM Online HD and programmer IEGM were available in 2099 arrhythmic or oversensing episodes, of which 146 (7.0%) were classified as other rhythm or artefacts in any IEGM (59 in both IEGMs, 36 in IEGM Online HD only, and 51 in programmer IEGM only). The final analysis was conducted with the remaining 1953 episodes in 352 patients, each contributing a median of two episodes (interquartile range, 1–5).

In 1803 of the 1953 episodes (92.3%), rhythm classifications by the investigators were identical for IEGM Online HD and programmer IEGM. The proportion of identical classifications did not vary significantly by device type (single-chamber ICD: 93.0%; dual-chamber ICD: 92.3%; CRT-D: 91.6%; all P > 0.4) (Table 2).

The most common arrhythmia, AF, accounting for 41.8% of all events, and T-wave oversensing were the most correctly classified events (each 94.6%), followed by VT (93.9%), SVT other than AF...
Table 3  Details of rhythm classification by investigators

| Programmer IEGM arrhythmia | IEGM online HD |       |       |       |       |       |
|---------------------------|----------------|-------|-------|-------|-------|-------|
|                           | VF  | VT  | AF   | Other SVT | Lead* | T-wave* |
| VF                        | 68  | 20  | 17   | 1      | 0     | 0      |
| VT                        | 24  | 443 | 2    | 1      | 1     | 1      |
| AF                        | 3   | 5   | 772  | 35     | 1     | 0      |
| Other SVT                 | 1   | 13  | 17   | 395    | 0     | 0      |
| Lead-related oversensing  | 2   | 0   | 0    | 1      | 37    | 0      |
| T-wave oversensing        | 0   | 5   | 0    | 0      | 0     | 88     |

The values in bold indicate equal classifications based on IEGM Online HD and Programmer IEGM.
AF, atrial fibrillation; HD, high definition; IEGM, intracardiac electrogram; SVT, supraventricular tachyarrhythmia; VF, ventricular fibrillation; VT, ventricular tachycardia.

*Lead-related or T-wave oversensing.

Figure 2  A borderline case between VF and fast polymorphic VT. The investigator opted for VT in the IEGM Online (upper panel) and for VF in the programmer IEGM (lower panel). Both IEGMs show a similar pre-detection arrhythmia appearance. Note that the programmer IEGM continues also during capacitor charging (to save space, only the beginning of charging is shown in the figure), which provides additional information for arrhythmia classification. A, atrium; Ars, atrial refractory sensed beat; As, atrial sensed beat; ATP, antitachycardia pacing; LV, left ventricle; LVp, left ventricular paced beat; LVs, left ventricular sensed beat; RV, right ventricle; RVs, right ventricular sensed beat; RVp, right ventricular paced beat; VF, ventricular fibrillation; VT1, slow ventricular tachycardia; VT2, fast ventricular tachycardia.
forms. The resulting classification accuracy of 97.2% in our study (Table 2) was significantly better than the 93.4% accuracy reported by the RIONI investigators (P = 0.004, χ² test). The recognition of supraventricular arrhythmia, including AF, was improved from 75.7% (RIONI) to 98.1% (LION; P < 0.001, χ² test).

Discussion

In this large-scale study conducted in a real-world setting, the accuracy of rhythm classification based on the IEGM Online HD was 92.3% for the six rhythm categories: VT, VF, AF, other SVT, oversensing due to lead failure, and T-wave oversensing. For basic rhythm classification as ventricular, supraventricular, or oversensing, it was 97.2%.

Owing to its graphic content, IEGMs are relatively large files for remote transmission compared with numerical data. In the remote monitoring system used in this study, the length of transmitted IEGM tracings is limited to reduce the energy consumption of the implanted devices. The first and second generation of IEGM Online were clinically evaluated in the RIONI and LION studies, respectively.

Comparison of Reliability of IEGM Online Interpretation and Lumax and IEGM Online HD Evaluation results

The RIONI study indicated that arrhythmia classification based on the first-generation IEGM Online left some room for improvement, as 6.6% of IEGMs were not classified correctly as ventricular, supraventricular, or oversensing events, after exclusion of 12.4% of IEGMs as inconclusive. In LION, only 2.8% of classifications into these three basic rhythm categories were incorrect, after excluding 7.0% episodes as inconclusive. The observed improvement with the second-generation IEGM Online was driven by enhanced discrimination between supraventricular and ventricular tachyarrhythmias.

Detailed rhythm classifications, studied only in LION, were correct in 64.7% of cases with VF and in 92.8%–94.6% of cases with VT, AF, other SVT, T-wave oversensing, and lead-related oversensing.

Two methodological differences between LION and the RIONI study are worth mentioning: the number of evaluated events was 10-fold larger in LION (2099 vs. 210), and IEGMs were interpreted by clinical investigators (LION) rather than three members of an expert board (RIONI). These differences imply that LION results may be more generalizable.

Reasons for arrhythmia misclassifications in Lumax and IEGM Online HD Evaluation

Incorrect VF classifications were mostly caused by confusion of VF with polymorphic VT that are difficult to discriminate without the morphology information from surface ECG. Likewise, AF is in IEGM often similar to atrial flutter, in this study classified as ‘other SVT’.

Since the LION study protocol did not require systematic collection of programmer IEGM printouts for a post-hoc analysis of reasons for misclassification, we are not able to systematize and quantify the reasons. However, the fact that all types of misclassifications, except for VT vs. VF, and for AF vs. other SVT, occurred with a similar rate indicates that the quality of the IEGM Online does not have a specific weakness. We also cannot exclude that some misclassifications were by mistake (reflecting a subjective error rate of investigators) rather than due to a deficiency of the IEGM Online.

Intracardiac electrogram in other remote cardioverter-defibrillator monitoring systems

Other remote ICD monitoring technologies transmit uncompressed full-length IEGMs that can probably be interpreted identically to the corresponding programmer IEGMs, although this has not been confirmed by clinical studies. However, these systems do not transmit data on a daily basis and usually require certain degree of patient compliance, so that a problem obviating transmissions may remain unnoticed for a longer period, along with silent arrhythmia during that period.

Benefit of remote monitoring

The analysis of episode IEGMs is an essential element of the follow-up of patients with an ICD. The good accuracy of remote IEGM classification that we are able to report is important and reassuring because remote monitoring of implantable electronic cardiac devices is rapidly becoming the standard of care. It had already led to a new organization of care based on dedicated allied professionals and/or the creation of remote monitoring units. The goals are to improve the quality of care for the patients and increase efficiency for the healthcare providers. The medical benefit of remote monitoring has been increasingly substantiated by randomized, controlled clinical trials, such as TRUST, CONNECT, COMPAS, and EVOLVO.

Recently, the IN-TIME landmark trial showed a reduced risk for a worsened clinical composite score combining death, hospitalization for heart failure, NYHA class, and patient global self-assessment in remotely monitored heart failure patients with ICDs and CRT-Ds, along with all-cause mortality reduction after one year. While a deeper understanding of the mechanisms of the clinical benefit of remote monitoring is still lacking, it is plausible that the continuous information about the patient’s status, especially when worsening, and the appropriate reaction of the physician are the two main contributing mechanisms. To get immediate information about arrhythmias is a major requirement in this process, and IEGM tracings are essential for arrhythmia classification.

Study limitations

The major limitation of the LION study was that usually the same investigators evaluated the IEGM Online HD and the programmer IEGM for the same episode, without being blinded to the link between the IEGMs. Investigators might have also omitted IEGMs
that were difficult to interpret; however, we deem that the large number of patients and investigators contributing episodes and their classifications reduce this potential bias. Furthermore, investigators may have classified the episodes concordant with the device’s episodes classification.

In the final analysis, 146 episodes (7.0%) classified as ‘other rhythm or artefact’ in one or both IEGMs were excluded. In these episodes, only a post hoc subjective interpretation of the equivalence of free-text entries describing the rhythm was possible to perform, which would not be scientifically sound for reporting.

Conclusion

The second-generation IEGM Online was evaluated in a large-scale study, based on 2099 arrhythmic and oversensing events affecting 352 of 1533 patients enrolled at 67 investigational sites. The underlying rhythm shown in IEGMs was correctly classified as VF, VT, AF, other SVT, lead-related oversensing, or T-wave oversensing in 92.3% of events. A rough rhythm classification as ventricular, supraventricular, or oversensing was correct in 97.2% of events, as compared with 93.4% for the first-generation IEGM Online in a previous publication.8

The LION study demonstrates that remote IEGM analysis is highly accurate in a remote monitoring system that transmits shorter IEGM than the full-length programmer IEGM for the sake of frequent, fully automatic data transmission.

Supplementary material

Supplementary material is available at Europace online.

Acknowledgements

The authors would like to thank Sabine Mitzenheim and Herdis Bender, PhD, for study management, Jochen Proff for scientific input, and Dejan Danilovic, PhD, for medical writing assistance.

Conflict of Interest: H.N. and E.V. have (also received speaker fees) from Biotronik. H.O. is conducting research sponsored by Biotronik, Medtronic, St. Jude Medical and Sorin, has received consulting fees from Biotronik and Medtronic, and lecture fees from Biotronik, Medtronic and St. Jude Medical. S.R. reports receiving honoraria for lectures from Medtronic, Sorin and travel grants from Biotronik, Boston Scientific, Medtronic and Sorin. J.S. is a full-time employee of Biotronik. G.Z. has received lecture fees from Biotronik and Medtronic. All other authors reported no conflict of interest.

Funding

The study was supported by Biotronik SE & Co. KG, Berlin, Germany. Funding to pay the Open Access publication charges for this article was provided by Biotronik.

References

1. Auricchio A, Hartung W, Geller C, Klein H. Clinical relevance of stored electrograms for implantable cardioverter-defibrillator (ICD) troubleshooting and understanding of mechanisms for ventricular tachyarrhythmias. Am J Cardiol 1996;78(5A):33–41.
2. Dubner S, Auricchio A, Steinberg JS, Vardas P, Stone P, Brugada J et al. ISHNE/EHRA expert consensus on remote monitoring of cardiovascular implantable electronic devices (CIEDs). Europace 2012;14:278–93.
3. Wilkoff BL, Auricchio A, Brugada J, Cowie M, Ellenbogen KA, Gillis AM et al. HRS/ EHRA Expert Consensus on the Monitoring of Cardiovascular Implantable Electronic Devices (CIEDs): description of techniques, indications, personnel, frequency and ethical considerations. Europace 2008;10:707–25.
4. Halimi F, Cantu F. Remote monitoring for active cardiovascular implantable electronic devices: a European survey. Europace 2010;12:1778–80.
5. Ritter O, Bauer WR. Use of “IEGM Online” in ICD patients - early detection of inappropriate classified ventricular tachycardia via Home Monitoring. Clin Res Cardiol 2006;95:368–72.
6. Jung W, Rilling A, Birkenheyer R, Miljak T, Meyerfeldt U. Advances in remote monitoring of implantable pacemakers, cardioverter defibrillators and cardiac resynchronisation therapy systems. J Interv Card Electrophysiol 2008;23:73–85.
7. Burri H, Senauf D. Remote monitoring and follow-up of pacemakers and implantable cardioverter defibrillators. Europace 2009;11:701–9.
8. Perings C, Bauer WR, Bondie HJ, Mewis C, James M, Bocker D et al. Remote monitoring of implantable-cardioverter defibrillators: results from the Reliability of IEGM Online Interpretation (RIONI) study. Europace 2011;13:221–9.
9. Ricci RP, Morichelli L, Santini M. Home monitoring remote control of pacemaker and implantable cardioverter defibrillator patients in clinical practice: impact on medical management and health-care resource utilization. Europace 2008;10:164–70.
10. Varma N, Epstein AE, Irmenp A, Schweikert R, Love C. Efficacy and safety of automatic remote monitoring for implantable cardioverter-defibrillator follow-up: the Luminos-T Safety Reduces Routine Office Device Follow-up (TRUST) trial. Circulation 2010;122:335–32.
11. Varma N, Michalski J, Epstein AE, Schweikert R. Automatic remote monitoring of implantable cardioverter-defibrillator lead and generator performance the Luminos-T Safety ReadySuR Routine Office Device Follow-up (TRUST) trial. Circ Arrhythm Electrophysiol 2010;3:328–36.
12. Guédon-Moreau L, Chavelier P, Marque C, Kousakam C, Kugl D, Lacroix D et al. Contributions of remote monitoring to the follow-up of implantable cardioverter-defibrillator leads under advisory. Eur Heart J 2010;31:2246–52.
13. Hindricks G, Elsner C, Piorkowski C, Taborsky M, Geller JC, Schumacher B et al. Quarterly vs. yearly clinical follow-up of remotely monitored recipients of prophylactic implantable cardioverter-defibrillators: results of the REFORM trial. Eur Heart J 2014;35:98–105.
14. Crossley GH, Boyle A, Vitense H, Chang Y, Mead RH. The CONNECT (Clinical Evaluation of Remote Notification to Reduce Time to Clinical Decision) trial: the value of wireless remote monitoring with automatic clinician alerts. J Am Coll Cardiol 2011;57:1181–9.
15. Brugada P. What evidence do we have to replace in-hospital implantable cardiover- ter-defibrillator follow-up? Clin Res Cardiol 2006;95(Suppl 3):iii3–9.
16. Landolino M, Perego GB, Lunati M, Cusma A, Guenzati G, Vicentini A et al. Remote monitoring reduces healthcare use and improves quality of care in heart failure patients with implantable defibrillators: the evolution of management strategies of heart failure patients with implantable defibrillators (EVELO) study. Circulation 2012;125:2985–92.
17. Müller A, Goette A, Perings C, Nagel H, Konorza T, Spitzer W et al. Potential role of telemedical service centers in managing remote monitoring data transmitted daily by cardiac implantable electronic devices: results of the early detection of cardiovascular events in device patients with heart failure (detect-T-Pilot) study. Telemed J E Health 2013;19:460–6.
18. Mabo P, Victor F, Bazin P, Ahres S, Babuty D, Da Costa A et al. A randomized trial of long-term remote monitoring of pacemaker recipients (The COMPAS trial). Eur Heart J 2012;33:1105–11.
19. Hindricks G, Taborsky M, Gilson M, Heinrich U, Schumacher B, Katz A et al. Implant-based multiparameter telemonitoring of patients with heart failure (IN-TIME): a randomised controlled trial. Lancet 2014;384:583–90.